Figure 4 shows the prevalence of pregnancies exposed to any ADM in the GDM group, as well as the prevalence of pregnancies exposed to an insulin product exclusively, a blood glucose-lowering drug exclusively, or both an insulin product and a blood glucose-lowering drug in this group, per year between 2012 and 2019 (see Supplementary Table 7). Supplementary Table 8 and Supplementary Figure 4 show the distribution of the different insulin and blood glucose-lowering drugs prescriptions in the GDM group during or after T2, overall and per year between 2012 and 2019. The gene discussed is INS; the disease is gestational diabetes.